This study demonstrates that CD26 CAR-M effectively targets and phagocytizes CD26-positive CML cells, implying that targeting CD26 with CAR-M could be a viable method for eradicating CML-LSCs. The gene discussed is DPP4; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.